Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OrthoAlloUnion for delayed union and non-union long bone fractures
2025-520841-60-00Phase 3Authorised
- Sponsor
- Fundación de Investigación Biomédica Hospital Puerta de Hierro
- Start
- Apr 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of ORTHOALLO-BM-MSC in fracture nonunion and delayed bone healing, sponsored by Fundación de Investigación Biomédica Hospital Puerta de Hierro. Primary endpoint: Radiological consolidation at 12 months. Planned start Apr 2026; status: authorised.
02
Drugs
ORTHOALLO-BM-MSC
03
Conditions
fracture nonuniondelayed bone healing
Beyond the preview
Go deeper on 2025-520841-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520841-60-00.